Amany ahmed’s Post

Assessing the benefits of #immunotherapy requires long-term follow-up. I'm thrilled to share the latest findings from the Phase 2 CheckMate 040 trial (Cohort 4) on #nivolumab and #ipilimumab for unresectable #HCC: ✅ 5 years post-treatment, nivolumab plus ipilimumab showed sustained benefits for sorafenib-treated advanced HCC. ✅ Durable responses (median duration: 51.2 months) and significant long-term survival (5-year rate: 29%) in arm A. ✅ No new safety concerns or additional discontinuations due to immune-mediated adverse events. Honoured to have been part of the authors' team ✨ Looking forward to the full results of the positive Phase 3 CheckMate 9DW trial. 🎯 Free full text: https://lnkd.in/dpCDDdnT #CancerResearch #Oncology #ClinicalTrials

🌟 𝐂𝐚𝐥𝐪𝐮𝐞𝐧𝐜𝐞 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐂𝐨𝐧𝐟𝐢𝐫𝐦𝐞𝐝: 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚 𝐒𝐡𝐚𝐫𝐞𝐬 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐌𝐚𝐧𝐭𝐥𝐞 𝐂𝐞𝐥𝐥 𝐋𝐲𝐦𝐩𝐡𝐨𝐦𝐚 𝐃𝐚𝐭𝐚 📈 𝗜𝗻 𝗝𝘂𝗻𝗲 𝟮𝟬𝟮𝟰, AstraZeneca has provided data to support its claim that its #blood #cancer medication #Calquence, when combined with #chemotherapy and #immunotherapy, is effective in treating patients with mantle #celllymphoma (MCL) who had not had prior treatment, as shown six weeks ago in an interim analysis of a phase 3 trial. The ECHO research found that a 27% lower risk of disease progression or mortality was associated with the addition of Calquence to the bendamustine and rituximab (BR) combination. At the European Haematology Association (EHA) Congress in Madrid, AstraZeneca revealed the trial results, saying that the amount is both statistically and clinically significant. A median progression-free survival (PFS) of 66.4 months was achieved with the Calquence combo in the research, which involved 𝟮𝟵𝟵 patients in each arm who were 65 years of age or older, as opposed to 𝟰𝟵.𝟲 months with BR alone. Furthermore, Calquence demonstrated a positive #trend in overall survival (OS), a first for a #BTK #inhibitor. AstraZeneca emphasized that OS will continue to be evaluated as a secondary endpoint in the ongoing trial and that the data has not yet reached maturity. 𝗟𝗼𝗼𝗸 𝗮𝘁 𝗼𝘂𝗿 𝗖𝗼𝗿𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3WJQN2D #Calquence #MantleCellLymphoma #CancerResearch #Oncology #ClinicalData #CancerTreatment #MedicalBreakthrough #Hematology #InnovativeTherapy #prophecymarketinsights

Breast cancer prevention includes, among others, regular breast self-examination and imaging tests (e.g. mammography). Based on a careful risk assessment, health care providers sometimes recommend drug therapy to reduce the risk of breast cancer in women who are at increased risk. These drugs include selective estrogen receptor modulators (SERMs) such as tamoxifen and raloxifene. They work by blocking the effects of estrogen on breast tissue. These drugs are only effective in preventing cancers that are known to be dependent on female hormones. Another category of drugs that may reduce the risk of breast cancer are aromatase inhibitors (AIs). However, these drugs have not yet received FDA approval for this use. They work by blocking the enzyme (aromatase), which is responsible for the production of estrogen in the body. AIs are contraindicated in women with intact ovarian function. The choice of therapy should be individual and take into account the risk profile of the specific treatment and the patient's preferences. Particular consideration should be given to the risk of thromboembolism, bone mineral density, and the occurrence of menopause. #NeoInsight #Healthcare #BreastCancer #Risk #Cancer #Oncology #OncologyPatient #MedicalResearch #SERM #AI #Mammography

Advances in cancer treatment means more options to select from, which also means juggling and balancing the toxicities of each to find the best fit for your patient Melanoma treatments have made tremendous strides in the last 10+ years, giving us many BRAF/MEK inhibitor combinations that are effective Multiple options is great, and it brings challenges because they have not been compared head-to-head. In terms of efficacy, they are currently viewed as equals. However, in clinical practice, their respective toxicity profiles differ substantially. Some adverse effects (AEs) are class effects 👇 ❤️ BRAF is associated with QT prolongation and MEK with reduced ejection fraction ❤️ And some are unique to each combination 👇 ☀️ Vemurafenib + cobimetinib can cause photosensitivity, severe rash, liver toxicity, and arthralgias 🤒 Dabrafenib + trametinib has the highest risk of flu-like symptoms (fever, chills, rigors), but is more commonly used as toxicity is generally more manageable than the others 👀 Encorafenib + binimetinib is better tolerated than the first two, although it carries a higher risk of acute visual changes 👀 (evaluate within 24 hours to rule out serious ocular issues like serous retinopathy, retinal vein occlusion, and uveitis) --- 📌 When you’re ready to prioritize learning oncology, the Enjoy Learning Oncology (ELO) program can help you! Click the **LEARN ONCOLOGY** link in my profile. I’m the Kelley in KelleyCPharmD 👋 and I help pharmacists learn the complex world of oncology #LearnOncology #Pharmacists #OncologyPharmacists #ClinicalPearls #Oncology

When there are multiple treatment options, #oncologypharmacists can help identify which one is the best fit with a patient’s other medications and co-morbid conditions

A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved efficacy of first-line nivolumab plus ipilimumab in patients with advanced renal cell carcinoma (aRCC). In the phase 3 JAVELIN Renal 101 trial, first-line avelumab plus axitinib significantly improved progression-free survival and objective response rate compared with sunitinib in patients with aRCC; however, the relationship between NER and clinical outcomes is unknown. In this post hoc analysis from the JAVELIN Renal 101 trial, baseline NER <median appeared to be prognostic for longer overall survival irrespective of treatment. Analyses that assessed the relationship between NER level and treatment outcomes were inconclusive but suggested a stronger association for avelumab plus axitinib versus sunitinib, particularly in patients with PD-L1+ tumours. All analyses reported are exploratory and were performed for hypothesis-generating purposes only Read the full study on BMJ Oncology now: https://lnkd.in/eNDbeCmy Check out this linked editorial from Kosuke Takemura and Daniel Y C Heng: https://lnkd.in/g3FPT8MD

When neurotoxicity comes knocking 🚪 Ifosfamide, a cytotoxic agent used for treating sarcomas and some other cancers, is known to cause neurotoxicity, which can manifest as encephalopathy in as many as 30% of patients 🧠 Patients get a lot of hydration and mesna (2-MercaptoEthane Sulfonate Na) with ifosfamide, and although mesna helps to prevent hemorrhagic cystitis, it does not prevent neurotoxicity 🙁 People are more likely to experience ifosfamide-induced neurotoxicity if they have impaired kidney function and low albumin To mitigate the risk of ifosfamide-induced encephalopathy, we monitor serum electrolytes, especially sodium levels, because ifosfamide can cause inappropriate antidiuretic hormone secretion (SIADH) Patients experiencing neurotoxicity may present with confusion 😕, hallucinations 😵💫, or somnolence 😴 and need prompt intervention. It is common for infusion centers to use a neurotoxicity checklist to assess patients daily. If neurotoxicity occurs, ifosfamide is stopped and methylene blue may be given, depending on the severity and clinical context We don’t know the mechanism of why methylene blue works, but it’s thought to prevent the accumulation of the toxic metabolite, chloroethylamine --- 📌 When you’re ready to prioritize learning oncology, the Enjoy Learning Oncology (ELO) program can help you! Check out the **LEARN ONCOLOGY** link in my profile. I’m the Kelley in KelleyCPharmD 👋 and I help pharmacists learn the complex world of oncology #LearnOncology #Pharmacists #OncologyPharmacists #ClinicalPearls #Oncology

On Medthority, key outcome data in pivotal #clinicaltrials investigating metastatic #prostatecancer - PROfound, PROpel, TALAPRO-2, TRITON-3, TheraP, and VISION. Follow the link https://lnkd.in/gDJQUPfX #mCRPC #cancer #MedEd #oncology

NEW from #ESMOGI2024 | Safety concerns of using #HER2-targeting therapies in #gastrointestinalcancers 🎥 🇩🇪 Sara Lonardi, MD, Veneto Institute of Oncology, addresses safety considerations when utilizing #HER2-directed therapies in #gastrointestinalcancers While rare, there is a risk of developing interstitial #lungdisease (ILD) with #trastuzumab #deruxtecan 💡 Prompt recognition of grade 1 toxicity symptoms is crucial, following clinical guidelines that recommend discontinuing treatment until ILD resolves to grade 0, followed by corticosteroids 💡 Escalation to grade 2 toxicity necessitates discontinuation of trastuzumab deruxtecan 💡 Managing other toxicity symptoms such as nausea and vomiting with anti-emetic medications is feasible, but maintaining the balance between symptom relief and preserving the efficacy of anticancer treatment remains pivotal Learn more 👉 https://lnkd.in/eDMaNa5X #VJOncology #Oncologynews

#ClinicalMonday: FDA Durvalumab (Imfinzi) Approval Alert 🚨 We are thrilled to announce that the FDA has approved durvalumab (Imfinzi) 💊 in combination with chemotherapy (carboplatin + paclitaxel) for the treatment of primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). This marks a significant step forward in the fight against this challenging form of cancer. 🔬 Key Findings from the DUO-E Trial: - Patients with dMMR tumors showed remarkable progress, with median progression-free survival not reached in the durvalumab arm compared to 7 months in the placebo arm (HR: 0.42). - Overall, the combination therapy demonstrated significant efficacy, particularly benefiting those with dMMR tumors. 💊 Dosage: - bodyweight ≥30 kg: 1,120 mg durvalumab with chemo every 3 weeks for 6 cycles, then 1,500 mg every 4 weeks. - bodyweight <30 kg: 15 mg/kg durvalumab with chemo every 3 weeks for 6 cycles, then 20 mg/kg every 4 weeks. 🤒 Common Side Effects: Peripheral neuropathy, musculoskeletal pain, nausea, alopecia, fatigue, and more. This approval is a testament to the power of personalized medicine and brings new hope to patients with limited treatment options. ✨ Congratulations to AstraZeneca and the dedicated researchers who made this possible! #EndometrialCancer #FDAApproval #Durvalumab #CancerTreatment #Oncology #MedicalResearch #HealthcareInnovation Image source: FOXBusiness  https://lnkd.in/gRKVFGkf